Clinical trials: CAR-T Cell Immunotherapy
Diffuse Intrinsic Pontine Glioma, DIPG
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG).
- Conditions
- Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor
- Trial name
- NCT07680439
- Testing
- BCB-276
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- BrainChild Bio, Inc
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer.
- Trial name
- RELY-30 (NCT02917083)
- Testing
- CAR T Cells
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Baylor College of Medicine
Glioma
IL13Rα2 CAR-T for Patients With r/r Glioma
This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma.
- Trial name
- ENHANCING (NCT06355908)
- Testing
- IL13Rα2 CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yang Zhang
Lymphoma, B-Cell
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-CD22 CAR-T cells for the treatment of B cell lymphoma.
- Trial name
- NCT04715217
- Testing
- CD19-CD22 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanxi Province Cancer Hospital
Acute Lymphoblastic Leukemia, B-All
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells.
- Trial name
- NCT07328503
- Testing
- CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)